Collegium Pharmaceutical Q2 Earnings: Revenue Expected to Grow 24.2% YoY

Collegium Pharmaceutical is expected to report Q2 earnings with revenue growth of 24.2% YoY to $180.4 million and adjusted EPS of $1.85. Analysts have generally reconfirmed their estimates over the last 30 days, and the company has missed Wall Street's revenue estimates three times in the past two years. The branded pharmaceuticals segment has underperformed, with share prices down 3.1% on average over the last month.

Collegium Pharmaceutical (COLL) is poised to release its Q2 earnings report on August 7, 2025, with analysts expecting a 24.2% year-over-year (YoY) revenue growth to $180.4 million and an adjusted earnings per share (EPS) of $1.85 [2]. The consensus estimate, however, has remained relatively stable over the past 30 days, suggesting analysts' confidence in the company's performance [2].

Despite the positive revenue outlook, Collegium Pharmaceutical has a history of missing Wall Street's revenue estimates, with three misses in the past two years. This inconsistency may influence investors' expectations and the stock's reaction to the earnings report [2]. The branded pharmaceuticals segment has underperformed recently, with share prices down 3.1% on average over the last month, highlighting the broader industry's challenges [2].

Collegium Pharmaceutical's stock price is currently trading at $31.10, with an average analyst price target of $42.75. The company's earnings surprise history suggests that it has beaten consensus EPS estimates three times in the last four quarters, indicating a potential for positive earnings surprises [1]. However, the company's recent revenue misses and the overall underperformance of the branded pharmaceuticals segment may pose risks to its stock price.

Investors should closely monitor Collegium Pharmaceutical's earnings call for insights into business conditions and management's outlook, as these factors can significantly impact the company's near-term stock performance. Additionally, keeping an eye on the Zacks Earnings ESP and Zacks Rank can provide valuable clues about the likelihood of an earnings beat or miss [1].

References:

[1] https://finance.yahoo.com/news/collegium-pharmaceutical-coll-q2-earnings-140004094.html
[2] https://finance.yahoo.com/news/collegium-pharmaceutical-coll-q2-earnings-031122036.html